Skip to main content
Erschienen in: Current Diabetes Reports 7/2020

01.07.2020 | Other Forms of Diabetes and Its Complications (JJ Nolan and H Thabit, Section Editors)

Euglycemic Ketoacidosis

verfasst von: Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini

Erschienen in: Current Diabetes Reports | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Diabetic ketoacidosis is a life-threatening complication of diabetes characterized by hyperglycemia, acidosis, and ketosis. Ketoacidosis may occur with blood glucose level < 200 mg/dl (improperly defined as euglycemic ketoacidosis, euKA) and also in people without diabetes. The absence of marked hyperglycemia can delay diagnosis and treatment, resulting in potential serious adverse outcomes.

Recent Findings

Recently, with the wide clinical use of sodium glucose co-transporter 2 inhibitors (SGLT2i), euKA has come back into the spotlight. Use of SGLT2i use can predispose to the development of ketoacidosis with relatively low or normal levels of blood glucose. This condition, however, can occur, in the absence of diabetes, in settings such as pregnancy, restriction on caloric intake, glycogen storage diseases or defective gluconeogenesis (alcohol abuse or chronic liver disease), and cocaine abuse.

Summary

euKA is a challenging diagnosis for most physicians who may be misled by the presence of normal glycemia or mild hyperglycemia. In this article, we review pathophysiology, etiologies, clinical presentation and the management of euKA.
Literatur
1.
2.
Zurück zum Zitat Wang ZH, Kihl-Selstam E, Eriksson JW. Ketoacidosis occurs in both type 1 and type 2 diabetes— a population-based study from northern Sweden. Diabet Med. 2008 Jul 1;25(7):867–70.PubMedCrossRef Wang ZH, Kihl-Selstam E, Eriksson JW. Ketoacidosis occurs in both type 1 and type 2 diabetes— a population-based study from northern Sweden. Diabet Med. 2008 Jul 1;25(7):867–70.PubMedCrossRef
5.
Zurück zum Zitat Jenkins D, Close CF, Krentz AJ, Nattrass M, Wright AD. Euglycaemic diabetic ketoacidosis : does it exist? Acta Diabetol. 1993;30(4):251–3. Jenkins D, Close CF, Krentz AJ, Nattrass M, Wright AD. Euglycaemic diabetic ketoacidosis : does it exist? Acta Diabetol. 1993;30(4):251–3.
6.
Zurück zum Zitat Guo R-X, Yang L-Z, Li L-X, Zhao X-P. Diabetic ketoacidosis in pregnancy tends to occur at lower blood glucose levels: case–control study and a case report of euglycemic diabetic ketoacidosis in pregnancy. J Obstet Gynaecol Res. 2008 Jun 1;34(3):324–30.PubMedCrossRef Guo R-X, Yang L-Z, Li L-X, Zhao X-P. Diabetic ketoacidosis in pregnancy tends to occur at lower blood glucose levels: case–control study and a case report of euglycemic diabetic ketoacidosis in pregnancy. J Obstet Gynaecol Res. 2008 Jun 1;34(3):324–30.PubMedCrossRef
7.
Zurück zum Zitat Joseph F, Anderson L, Goenka N, Vora J. Starvation-induced true diabetic euglycemic ketoacidosis in severe depression. J Gen Intern Med. 2008;24(1):129.PubMedPubMedCentralCrossRef Joseph F, Anderson L, Goenka N, Vora J. Starvation-induced true diabetic euglycemic ketoacidosis in severe depression. J Gen Intern Med. 2008;24(1):129.PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Stoimenis D, Spyridonidou C, Theofanidou S, Petridis N, Papaioannou N, Iasonidou C, et al. Euglycemic ketoacidosis in spinal muscular atrophy. Case Rep Pediatr. 2019;2019:2862916.PubMedPubMedCentral Stoimenis D, Spyridonidou C, Theofanidou S, Petridis N, Papaioannou N, Iasonidou C, et al. Euglycemic ketoacidosis in spinal muscular atrophy. Case Rep Pediatr. 2019;2019:2862916.PubMedPubMedCentral
9.
Zurück zum Zitat Lee SH, Park JH, Hong M-K, Hyeon S, Kim MY, Lee SE, et al. True euglycemic diabetic ketoacidosis in a person with type 2 diabetes and Duchenne muscular dystrophy. Diabetes Res Clin Pract. 2011;92(1):e7–8.PubMedCrossRef Lee SH, Park JH, Hong M-K, Hyeon S, Kim MY, Lee SE, et al. True euglycemic diabetic ketoacidosis in a person with type 2 diabetes and Duchenne muscular dystrophy. Diabetes Res Clin Pract. 2011;92(1):e7–8.PubMedCrossRef
11.
Zurück zum Zitat Nakamura K, Inokuchi R, Doi K, Fukuda T, Tokunaga K, Nakajima S, et al. Septic ketoacidosis. Intern Med. 2014;53(10):1071–3.PubMedCrossRef Nakamura K, Inokuchi R, Doi K, Fukuda T, Tokunaga K, Nakajima S, et al. Septic ketoacidosis. Intern Med. 2014;53(10):1071–3.PubMedCrossRef
12.
Zurück zum Zitat Prater J, Chaiban JT. Euglycemic diabetic ketoacidosis with acute pancreatitis in a patient not known to have diabetes. AACE Clin Case Rep. 2014;1(2):e88–91.CrossRef Prater J, Chaiban JT. Euglycemic diabetic ketoacidosis with acute pancreatitis in a patient not known to have diabetes. AACE Clin Case Rep. 2014;1(2):e88–91.CrossRef
13.
Zurück zum Zitat Abu-Abed Abdin A, Hamza M, Khan MS, Ahmed A. Euglycemic diabetic ketoacidosis in a patient with cocaine intoxication. Case Rep Crit Care. 2016;2016:4275651.PubMedPubMedCentral Abu-Abed Abdin A, Hamza M, Khan MS, Ahmed A. Euglycemic diabetic ketoacidosis in a patient with cocaine intoxication. Case Rep Crit Care. 2016;2016:4275651.PubMedPubMedCentral
14.
Zurück zum Zitat Bonora BM, Avogaro A, Fadini GP. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: an updated review of the literature. Diabetes Obes Metab. 2018;20(1):25–33.PubMedCrossRef Bonora BM, Avogaro A, Fadini GP. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: an updated review of the literature. Diabetes Obes Metab. 2018;20(1):25–33.PubMedCrossRef
15.
16.
Zurück zum Zitat Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015 Sep 1;38(9):1638–42.PubMedCrossRef Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015 Sep 1;38(9):1638–42.PubMedCrossRef
17.
Zurück zum Zitat Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75(12):1272–7.PubMedCrossRef Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75(12):1272–7.PubMedCrossRef
18.
Zurück zum Zitat • Nyenwe EA, Kitabchi AE. The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management. Metabolism. 2016;65(4):507–21. Detailed and updated review on etiology, pathogenesis and management of ketoacidosis. PubMedCrossRef • Nyenwe EA, Kitabchi AE. The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management. Metabolism. 2016;65(4):507–21. Detailed and updated review on etiology, pathogenesis and management of ketoacidosis. PubMedCrossRef
19.
Zurück zum Zitat Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013;1(2):140–51.PubMedCrossRef Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013;1(2):140–51.PubMedCrossRef
20.
Zurück zum Zitat Nathan DM. Adjunctive treatments for type 1 diabetes. N Engl J Med. 2017 Sep 13;377(24):2390–1.PubMedCrossRef Nathan DM. Adjunctive treatments for type 1 diabetes. N Engl J Med. 2017 Sep 13;377(24):2390–1.PubMedCrossRef
23.
Zurück zum Zitat Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia. 2017;60(8):1385–9.PubMedCrossRef Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia. 2017;60(8):1385–9.PubMedCrossRef
24.
Zurück zum Zitat Wang L, Voss EA, Weaver J, Hester L, Yuan Z, DeFalco F, et al. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases. Pharmacoepidemiol Drug Saf. 2019;28(12):1620–8.PubMedPubMedCentralCrossRef Wang L, Voss EA, Weaver J, Hester L, Yuan Z, DeFalco F, et al. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases. Pharmacoepidemiol Drug Saf. 2019;28(12):1620–8.PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med. 2017 Jun 7;376(23):2300–2.PubMedCrossRef Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med. 2017 Jun 7;376(23):2300–2.PubMedCrossRef
26.
Zurück zum Zitat Kim Y-G, Jeon JY, Han SJ, Kim DJ, Lee K-W, Kim HJ. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: a nationwide population-based cohort study. Diabetes Obes Metab. 2018 Aug 1;20(8):1852–8.PubMedCrossRef Kim Y-G, Jeon JY, Han SJ, Kim DJ, Lee K-W, Kim HJ. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: a nationwide population-based cohort study. Diabetes Obes Metab. 2018 Aug 1;20(8):1852–8.PubMedCrossRef
27.
Zurück zum Zitat Dandona P, Mathieu C, Phillip M, Hansen L, Tschöpe D, Thorén F, et al. Efficacy and safety of Dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care. 2018 Dec 1;41(12):2552–9.PubMedCrossRef Dandona P, Mathieu C, Phillip M, Hansen L, Tschöpe D, Thorén F, et al. Efficacy and safety of Dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care. 2018 Dec 1;41(12):2552–9.PubMedCrossRef
28.
Zurück zum Zitat Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care. 2018 Dec 1;41(12):2560–9.PubMedCrossRef Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care. 2018 Dec 1;41(12):2560–9.PubMedCrossRef
29.
Zurück zum Zitat Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care. 2015 Jul 1;38(7):1181–8.PubMedPubMedCentralCrossRef Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care. 2015 Jul 1;38(7):1181–8.PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015 Dec 1;38(12):2258–65.PubMedCrossRef Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015 Dec 1;38(12):2258–65.PubMedCrossRef
31.
Zurück zum Zitat Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, et al. Shift to fatty substrate utilization in response to sodium–glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016 May 1;65(5):1190–5.PubMedCrossRef Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, et al. Shift to fatty substrate utilization in response to sodium–glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016 May 1;65(5):1190–5.PubMedCrossRef
32.
Zurück zum Zitat Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 2010;1(2):57–92.PubMedPubMedCentralCrossRef Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 2010;1(2):57–92.PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499–508.PubMedPubMedCentralCrossRef Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499–508.PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thévenet J, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015 Apr 20;21:512–7.PubMedCrossRef Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thévenet J, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015 Apr 20;21:512–7.PubMedCrossRef
35.
Zurück zum Zitat Solini A, Sebastiani G, Nigi L, Santini E, Rossi C, Dotta F. Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells. Diabetes Metab. 2017;43(6):512–20.PubMedCrossRef Solini A, Sebastiani G, Nigi L, Santini E, Rossi C, Dotta F. Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells. Diabetes Metab. 2017;43(6):512–20.PubMedCrossRef
36.
Zurück zum Zitat Kuhre RE, Ghiasi SM, Adriaenssens AE, Wewer Albrechtsen NJ, Andersen DB, Aivazidis A, et al. No direct effect of SGLT2 activity on glucagon secretion. Diabetologia. 2019;62(6):1011–23.PubMedPubMedCentralCrossRef Kuhre RE, Ghiasi SM, Adriaenssens AE, Wewer Albrechtsen NJ, Andersen DB, Aivazidis A, et al. No direct effect of SGLT2 activity on glucagon secretion. Diabetologia. 2019;62(6):1011–23.PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat • Wang M, Yu X, Lee Y, McCorkle SK, Chen S, Li J, et al. Dapagliflozin suppresses glucagon signaling in rodent models of diabetes. Proc Natl Acad Sci. 2017;114(25):6611–6. Recently published paper on the ketogenic effects of SGLT2i that challenges the dogma that glucagon is a primary factor in the regulation of ketone production. PubMedCrossRef • Wang M, Yu X, Lee Y, McCorkle SK, Chen S, Li J, et al. Dapagliflozin suppresses glucagon signaling in rodent models of diabetes. Proc Natl Acad Sci. 2017;114(25):6611–6. Recently published paper on the ketogenic effects of SGLT2i that challenges the dogma that glucagon is a primary factor in the regulation of ketone production. PubMedCrossRef
38.
Zurück zum Zitat Capozzi ME, Coch RW, Koech J, Astapova II, Wait JB, Encisco SE, et al. The Limited role of glucagon for ketogenesis during fasting or in response to SGLT2 inhibition. Diabetes. 2020;69(5):882–92. Capozzi ME, Coch RW, Koech J, Astapova II, Wait JB, Encisco SE, et al. The Limited role of glucagon for ketogenesis during fasting or in response to SGLT2 inhibition. Diabetes. 2020;69(5):882–92.
39.
Zurück zum Zitat Larroumet A, Camoin M, Foussard N, Alexandre L, Mesli S, Redonnet I, et al. Euglycemic ketoacidosis induced by therapeutic fasting in a non-diabetic patient. Nutrition. 2020;72:110668.PubMedCrossRef Larroumet A, Camoin M, Foussard N, Alexandre L, Mesli S, Redonnet I, et al. Euglycemic ketoacidosis induced by therapeutic fasting in a non-diabetic patient. Nutrition. 2020;72:110668.PubMedCrossRef
40.
Zurück zum Zitat Owen D, Little S, Leach R, Wyncoll D. A patient with an unusual aetiology of a severe ketoacidosis. Intensive Care Med. 2008;34(5):971–2.PubMedCrossRef Owen D, Little S, Leach R, Wyncoll D. A patient with an unusual aetiology of a severe ketoacidosis. Intensive Care Med. 2008;34(5):971–2.PubMedCrossRef
41.
Zurück zum Zitat Wolfe RR, Peters EJ, Klein S, Holland OB, Rosenblatt J, Gary H. Effect of short-term fasting on lipolytic responsiveness in normal and obese human subjects. Am J Physiol Metab. 1987;252(2):E189–96. Wolfe RR, Peters EJ, Klein S, Holland OB, Rosenblatt J, Gary H. Effect of short-term fasting on lipolytic responsiveness in normal and obese human subjects. Am J Physiol Metab. 1987;252(2):E189–96.
42.
Zurück zum Zitat Jensen MD, Haymond MW, Gerich JE, Cryer PE, Miles JM. Lipolysis during fasting. Decreased suppression by insulin and increased stimulation by epinephrine. J Clin Invest. 1987 Jan;79(1):207–13.PubMedPubMedCentralCrossRef Jensen MD, Haymond MW, Gerich JE, Cryer PE, Miles JM. Lipolysis during fasting. Decreased suppression by insulin and increased stimulation by epinephrine. J Clin Invest. 1987 Jan;79(1):207–13.PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Burge MR, Hardy KJ, Schade DS. Short-term fasting is a mechanism for the development of euglycemic ketoacidosis during periods of insulin deficiency. J Clin Endocrinol Metab. 1993 May 1;76(5):1192–8.PubMed Burge MR, Hardy KJ, Schade DS. Short-term fasting is a mechanism for the development of euglycemic ketoacidosis during periods of insulin deficiency. J Clin Endocrinol Metab. 1993 May 1;76(5):1192–8.PubMed
44.
Zurück zum Zitat Sibai BM, Viteri OA. Diabetic ketoacidosis in pregnancy. Obstet Gynecol. 2014;123(1):167–78.PubMedCrossRef Sibai BM, Viteri OA. Diabetic ketoacidosis in pregnancy. Obstet Gynecol. 2014;123(1):167–78.PubMedCrossRef
45.
Zurück zum Zitat Parker JA, Conway DL. Diabetic ketoacidosis in pregnancy. Obstet Gynecol Clin N Am. 2007;34(3):533–43.CrossRef Parker JA, Conway DL. Diabetic ketoacidosis in pregnancy. Obstet Gynecol Clin N Am. 2007;34(3):533–43.CrossRef
46.
Zurück zum Zitat Ryan EA, Enns L. Role of gestational hormones in the induction of insulin resistance. J Clin Endocrinol Metab. 1988 Aug 1;67(2):341–7.PubMedCrossRef Ryan EA, Enns L. Role of gestational hormones in the induction of insulin resistance. J Clin Endocrinol Metab. 1988 Aug 1;67(2):341–7.PubMedCrossRef
47.
Zurück zum Zitat Jaber JF, Standley M, Reddy R. Euglycemic diabetic ketoacidosis in pregnancy: a case report and review of current literature. In: Waxman KS, editor. Case Reports Crit Care, vol. 2019; 2019. p. 8769714. Jaber JF, Standley M, Reddy R. Euglycemic diabetic ketoacidosis in pregnancy: a case report and review of current literature. In: Waxman KS, editor. Case Reports Crit Care, vol. 2019; 2019. p. 8769714.
49.
Zurück zum Zitat Burbos N, Shiner AM, Morris E. Severe metabolic acidosis as a consequence of acute starvation in pregnancy. Arch Gynecol Obstet. 2008;279(3):399.PubMedCrossRef Burbos N, Shiner AM, Morris E. Severe metabolic acidosis as a consequence of acute starvation in pregnancy. Arch Gynecol Obstet. 2008;279(3):399.PubMedCrossRef
50.
Zurück zum Zitat Patel A, Felstead D, Doraiswami M, Stocks GM, Waheed U. Acute starvation in pregnancy: a cause of severe metabolic acidosis. Int J Obstet Anesth. 2011;20(3):253–6.PubMedCrossRef Patel A, Felstead D, Doraiswami M, Stocks GM, Waheed U. Acute starvation in pregnancy: a cause of severe metabolic acidosis. Int J Obstet Anesth. 2011;20(3):253–6.PubMedCrossRef
51.
Zurück zum Zitat Dillon E, Dyer W, Smelo L. Ketone acidosis of non-diabetic adults. Med Clin North Am. 1940;24:1813–22.CrossRef Dillon E, Dyer W, Smelo L. Ketone acidosis of non-diabetic adults. Med Clin North Am. 1940;24:1813–22.CrossRef
52.
Zurück zum Zitat Umpierrez GE, DiGirolamo M, Tuvlin JA, Isaacs SD, Bhoola SM, Kokko JP. Differences in metabolic and hormonal milieu in diabetic- and alcohol-induced ketoacidosis. J Crit Care. 2000;15(2):52–9.PubMedCrossRef Umpierrez GE, DiGirolamo M, Tuvlin JA, Isaacs SD, Bhoola SM, Kokko JP. Differences in metabolic and hormonal milieu in diabetic- and alcohol-induced ketoacidosis. J Crit Care. 2000;15(2):52–9.PubMedCrossRef
54.
Zurück zum Zitat Chambrier C, Laville M, Rhzioual Berrada K, Odeon M, Boulètreau P, Beylot M. Insulin sensitivity of glucose and fat metabolism in severe sepsis. Clin Sci. 2000;99:321–8.PubMedCrossRef Chambrier C, Laville M, Rhzioual Berrada K, Odeon M, Boulètreau P, Beylot M. Insulin sensitivity of glucose and fat metabolism in severe sepsis. Clin Sci. 2000;99:321–8.PubMedCrossRef
55.
Zurück zum Zitat Segebrecht R, Moncure M, Bennett A, Geehan D, Van Way IIICW, Weide L. Ketoacidosis in euglycemic patients with type 2 diabetes after abdominal surgery. J Parenter Enter Nutr. 2019;43(7):937–40.CrossRef Segebrecht R, Moncure M, Bennett A, Geehan D, Van Way IIICW, Weide L. Ketoacidosis in euglycemic patients with type 2 diabetes after abdominal surgery. J Parenter Enter Nutr. 2019;43(7):937–40.CrossRef
56.
Zurück zum Zitat Arena FP, Dugowson C, Saudek CD. Salicylate-induced hypoglycemia and ketoacidosis in a nondiabetic adult. Arch Intern Med. 1978 Jul 1;138(7):1153–4.PubMedCrossRef Arena FP, Dugowson C, Saudek CD. Salicylate-induced hypoglycemia and ketoacidosis in a nondiabetic adult. Arch Intern Med. 1978 Jul 1;138(7):1153–4.PubMedCrossRef
57.
Zurück zum Zitat Kraut JA, Kurtz I. Toxic alcohol ingestions: clinical features, diagnosis, and management. Clin J Am Soc Nephrol. 2008 Jan 1;3(1):208–25.PubMedCrossRef Kraut JA, Kurtz I. Toxic alcohol ingestions: clinical features, diagnosis, and management. Clin J Am Soc Nephrol. 2008 Jan 1;3(1):208–25.PubMedCrossRef
58.
Zurück zum Zitat Alfadhel M, Babiker A. Inborn errors of metabolism associated with hyperglycaemic ketoacidosis and diabetes mellitus: narrative review. Sudan J Paediatr. 2018;18(1):10–23.PubMedPubMedCentral Alfadhel M, Babiker A. Inborn errors of metabolism associated with hyperglycaemic ketoacidosis and diabetes mellitus: narrative review. Sudan J Paediatr. 2018;18(1):10–23.PubMedPubMedCentral
59.
Zurück zum Zitat • Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, et al. American Association of Clinical Endocrinologists and American College of Endocrinolgy position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract. 2016;22(6):753–62. Detailed and comprehensive position statement specifically dedicated to the association of SGLT2i and Diabetic Ketoacidosis and for management of DKA in patients taking SGLT2i. PubMedCrossRef • Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, et al. American Association of Clinical Endocrinologists and American College of Endocrinolgy position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract. 2016;22(6):753–62. Detailed and comprehensive position statement specifically dedicated to the association of SGLT2i and Diabetic Ketoacidosis and for management of DKA in patients taking SGLT2i. PubMedCrossRef
60.
Zurück zum Zitat Le Neveu F, Hywel B, Harvey JN. Euglycaemic ketoacidosis in patients with and without diabetes. Pract Diabetes. 2013;30(4):167–71.CrossRef Le Neveu F, Hywel B, Harvey JN. Euglycaemic ketoacidosis in patients with and without diabetes. Pract Diabetes. 2013;30(4):167–71.CrossRef
Metadaten
Titel
Euglycemic Ketoacidosis
verfasst von
Benedetta Maria Bonora
Angelo Avogaro
Gian Paolo Fadini
Publikationsdatum
01.07.2020
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 7/2020
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-020-01307-x

Weitere Artikel der Ausgabe 7/2020

Current Diabetes Reports 7/2020 Zur Ausgabe

Economics and Policy in Diabetes (AA Baig and N Laiteerapong, Section Editors)

Managing Diabetes in Hard to Reach Populations: A Review of Telehealth Interventions

Economics and Policy in Diabetes (AA Baig and N Laiteerapong, Section Editors)

Economic Simulation Modeling in Type 2 Diabetes

Immunology, Transplantation, and Regenerative Medicine (L Piemonti and V Sordi, Section Editors)

Updates on Gene Therapy for Diabetic Retinopathy

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.